FDA Approval for ZORVOLEX™

October 18, 2013 – Iroko Pharmaceuticals, LLC, announced that the FDA had approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX™ was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.

The approval of ZORVOLEX™ is important news for patients and for physicians who need new options for pain relief.